Positive committee recommendation — pending FDA rulemaking
Where to Buy MOTS-c
MOTS-c gets no seller list here, and the empty board is a position this site is willing to explain rather than an omission.
MOTS-c turns up on telehealth menus more often than most compounds in its position, usually as a line item on a metabolic program, which does not make it comparable. The dated regulatory note on this board carries the status these decisions rest on.
A scored board needs sellers who publish enough for a reader to check them against each other. Appearing on a menu is not that: a compound can be listed, photographed and described at length while the terms of the actual purchase stay out of view.
So the ranking is withheld and the reason is printed. A reader who came here to buy leaves knowing what the obstacle is, which is more useful than a table assembled to fill the space.
Regulatory status, as of July 2026
MOTS-c drew the closest split of the July 23, 2026 session at the FDA Pharmacy Compounding Advisory Committee. The vote was 7-5 in favor of adding it to the Section 503A bulk drug substances list, with two abstentions. As with every peptide the committee advanced that week, the recommendation contradicts the FDA's own briefing position, which was that none of the fourteen peptide forms under review should be added. That is a committee overruling agency staff. Saying so is deliberate: the softer phrasing would leave a reader with the wrong impression of where this stands. The vote carries no legal force by itself. Compounding MOTS-c for patients remains unlawful unless the FDA accepts it and completes proposed and then final rulemaking. Both the result and the timing remain open.
Two things have to happen. The FDA has to finish rulemaking that puts MOTS-c on the 503A list. Then at least one verifiable US telehealth provider has to dispense it with a named pharmacy and a published, qualified price. That combination is what turns this into a scored board.
What this board covers
Nothing is ranked today. A compound earns a scored board on this site once a licensed US telehealth seller dispenses it under facts a reader can verify for themselves. A menu listing with no checkable terms behind it does not qualify, however prominent the listing is.
What MOTS-c is
MOTS-c is a short peptide encoded in mitochondrial DNA, so the body produces it natively. It is studied in connection with metabolic and exercise physiology. What is sold under the name is a synthetic copy, and no FDA-approved MOTS-c product exists. This page covers its regulatory status only.
What the evidence shows
The interesting part of the MOTS-c literature is mechanistic and observational. The part that would matter to a buyer, controlled trials of MOTS-c given as a therapy, has not been published. The grade is limited rather than absent because the underlying biology is real and has been measured in people. How an injected synthetic version behaves over time in humans has not been measured. Marketing copy conflates those two things constantly, and they are separated here on purpose.
What to watch for
- A menu listing with no price attached. It reads as an available product and functions as a lead capture, and the difference shows up only after an intake collects personal details.
- Mitochondrial biology doing the selling. The body producing a peptide natively says nothing about what an injected synthetic copy does, and marketing copy leans on that slide constantly.
- Exercise and metabolism research quoted as an outcome. Mechanism studies describe how something might work, not what happened to people who bought it.
- MOTS-c bundled into a broader program price. The figure then covers a package, and what the compound itself contributes to the bill is never broken out.
Frequently asked questions
Why does this board list no providers?
Because none can be compared here on published facts a reader could verify. The dated regulatory note on this board sets out the position behind that, on its own terms.
A telehealth company lists MOTS-c. Does that make it available?
A listing is not an offer. Without a published price, disclosed terms and a verifiable dispensing route, there is nothing for a comparison table to hold.
Does an empty board mean MOTS-c is dangerous?
No. The board reflects what can be lawfully dispensed and independently checked, not a judgment about harm. Those are different claims and this site keeps them apart.
Which compounds do have boards here?
The ones whose sellers publish enough to be compared against each other. Those boards are built from declared facts, and the related compounds listed below link straight into them.
Where is the status recorded?
In the dated regulatory note on this board, which carries its own as-of date. It is written to stand alone and is not paraphrased elsewhere on the site.